According to China’s 2023 Tariff Adjustment Plan, 1,020 categories of products can enjoy interim import tariffs that are lower than most-favored-nation (MFN) tariffs from Jan. 1, 2023.
Among the 1,020 categories of products, 22 are active pharmaceutical ingredients (APIs) of medicines for treating COVID-19, cancer, and rare diseases. Their provisional tariff rates are all cut to 0%.1
Tax Code | Product | 2023 MFN Tariff Rate % | 2023 Interim Tariff Rate% | |
29337900 | API of COVID-19 drug | Nirmatrelvir | 9 | 0 |
29309090 | APIs of rare disease / orphan drugs | Penicillamine | 6.5 | 0 |
29337900 | Pirfenidone | 9 | 0 | |
29342000 | Riluzole | 6.5 | 0 | |
29359000 | Bosentan | 6.5 | 0 | |
28439000 | APIs of anti-cancer drugs | Oxaliplatin; Carboplatin; Nedaplatin; Cisplatin | 5.5 | 0 |
29225090 | Mitoxantrone Hydrochloride | 6.5 | 0 | |
29242990 | Flutamide | 6.5 | 0 | |
29309090 | Bicalutamide | 6.5 | 0 | |
29329990 | Docetaxel; Paclitaxel | 6.5 | 0 | |
29334900 | Pyrotinib Maleate | 6.5 | 0 | |
29335990 | Imatinib Mesylate; Azathioprine; Pemetrexed Disodium; Calcium Levofolinate; Flumatinib Mesylate; Almonertinib Mesilate; Zanubrutinib | 6.5 | 0 | |
29336990 | Oteracil Potassium | 6.5 | 0 | |
29337900 | Lenalidomide | 9 | 0 | |
29339900 | Anastrozole; Letrozole; Bortezomib; Temozolomide | 6.5 | 0 | |
29341090 | Dasatinib | 6.5 | 0 | |
29349990 | Decitabine; Floxuridine; Cyclophosphamide; Gefitinib; Capecitabine; Raltitrexed; Fludarabine Phosphate; Tegafur; Cytarabine; Cytarabine Hydrochloride; Icotinib Hydrocholride; Gemcitabine Hydrochloride; Ifosfamide; Fruquintinib | 6.5 | 0 | |
29371900 | Triptorelin Acetate | 4 | 0 | |
29372319 | Formestane | 4 | 0 | |
29372900 | Exemestane | 4 | 0 | |
29397990 | Vinorelbine Tartrate; Vincristine Sulfate; Topotecan Hydrochloride; Irinotecan Hydrochloride | 4 | 0 | |
29419090 | Pirarubicin; Mitomycin; Epirubicin Hydrochloride; Doxorubicin Hydrochloride; Bleomycin A5 Hydrochloride; Daunorubicin Hydrochloride; | 6 | 0 | |
Since 2018, China has exempted the tariffs on APIs of the 1st and 2nd lists of anti-cancer and rare disease drugs, indicating the further opening of the Chinese pharma market.
Related: China Cuts VAT to 3% for the 3rd List of Anti-cancer and Rare Disease Drugs
